Skip to main content

Articles

Page 2 of 38

  1. BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase ...

    Authors: Kai Rejeski, Doris K. Hansen, Radhika Bansal, Pierre Sesques, Sikander Ailawadhi, Jennifer M. Logue, Eva Bräunlein, David M. Cordas dos Santos, Ciara L. Freeman, Melissa Alsina, Sebastian Theurich, Yucai Wang, Angela M. Krackhardt, Frederick L. Locke, Emmanuel Bachy, Michael D. Jain…
    Citation: Journal of Hematology & Oncology 2023 16:88
  2. NEDDylation, a post-translational modification through three-step enzymatic cascades, plays crucial roles in the regulation of diverse biological processes. NEDD8-activating enzyme (NAE) as the only activation...

    Authors: Dong-Jun Fu and Ting Wang
    Citation: Journal of Hematology & Oncology 2023 16:87
  3. Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen (BCMA) has demonstrated incredible results, leading to regulatory approva...

    Authors: James F. Wu and Binod Dhakal
    Citation: Journal of Hematology & Oncology 2023 16:86
  4. Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the ...

    Authors: Jiazheng Yu, Siyu Wu, Rong Li, Yuanhong Jiang, Jianyi Zheng, Zeyu Li, Mingyang Li, Kerong Xin, Xiaojiao Guan, Shijie Li and Xiaonan Chen
    Citation: Journal of Hematology & Oncology 2023 16:85
  5. Hyperhomocysteinemia (HHcy) is closely associated with thrombotic diseases such as myocardial infarction and stroke. Enhanced platelet activation was observed in animals and humans with HHcy. However, the infl...

    Authors: Wenjing Lei, Zhuoliang Liu, Zhiyuan Su, Panpan Meng, Chun Zhou, Xiaomei Chen, Zheng Hu, An Xiao, Miaomiao Zhou, Liping Huang, Yiyue Zhang, Xianhui Qin, Junping Wang, Fengxin Zhu and Jing Nie
    Citation: Journal of Hematology & Oncology 2023 16:84
  6. Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, anemia, extramedullary hematopoiesis, and splenomegaly. Patients with MF are at risk for reduced survival vers...

    Authors: Srdan Verstovsek, Ruben A. Mesa, Robert A. Livingston, Wilson Hu and John Mascarenhas
    Citation: Journal of Hematology & Oncology 2023 16:82
  7. Authors: N. Lopez-Muñoz, G. Hernández-Ibarburu, R. Alonso, J. M. Sanchez-Pina, R. Ayala, M. Calbacho, C. Cuellar, M. T. Cedena, A. Jiménez-Ubieto, R. Iñiguez, M. Pedrera, J. Cruz, L. Meloni, D. Pérez-Rey, P. Serrano, J. de la Cruz…
    Citation: Journal of Hematology & Oncology 2023 16:81

    The original article was published in Journal of Hematology & Oncology 2023 16:76

  8. Tumour-associated macrophages (TAMs) are crucial components of the tumour microenvironment and play a significant role in tumour development and drug resistance by creating an immunosuppressive microenvironmen...

    Authors: Mengyuan Li, Yuhan Yang, Liting Xiong, Ping Jiang, Junjie Wang and Chunxiao Li
    Citation: Journal of Hematology & Oncology 2023 16:80
  9. Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalat...

    Authors: Maria-Luisa Schubert, Anita Schmitt, Angela Hückelhoven-Krauss, Brigitte Neuber, Alexander Kunz, Philip Waldhoff, Dominik Vonficht, Schayan Yousefian, Lea Jopp-Saile, Lei Wang, Felix Korell, Anna Keib, Birgit Michels, Dominik Haas, Tim Sauer, Patrick Derigs…
    Citation: Journal of Hematology & Oncology 2023 16:79
  10. The rapidly increasing use of high-throughput screening had produced a plethora of expanding knowledge on the molecular basis of natural killer/T-cell lymphoma (NKTCL), which in turn has revolutionized the tre...

    Authors: Xiao-Peng Tian, Yi Cao, Jun Cai, Yu-Chen Zhang, Qi-Hua Zou, Jin-Ni Wang, Yu Fang, Jia-Hui Wang, Song-Bin Guo and Qing-Qing Cai
    Citation: Journal of Hematology & Oncology 2023 16:78
  11. The receptor tyrosine kinases TAM family (TYRO3, AXL, and MERTK) are highly expressed in multiple forms of cancer cells and tumor-associated macrophages and promote the development of cancers including pancrea...

    Authors: Jiawei Fan, Ye Yu, Lanzhen Yan, Yuncang Yuan, Bin Sun, Dong Yang, Nan Liu, Jing Guo, Jie Zhang and Xudong Zhao
    Citation: Journal of Hematology & Oncology 2023 16:77
  12. Survival in multiple myeloma has improved significantly in recent years, especially in young patients. We reviewed the evolution of the survival of patients with MM in three groups based on age at MM diagnosis...

    Authors: N. Lopez-Muñoz, G. Hernández-Ibarburu, R. Alonso, J. M. Sanchez-Pina, R. Ayala, M. Calbacho, C. Cuellar, M. T. Cedena, A. Jiménez-Ubieto, R. Iñiguez, M. Pedrera, J. Cruz, L. Meloni, D. Pérez-Rey, P. Serrano, J. de la Cruz…
    Citation: Journal of Hematology & Oncology 2023 16:76

    The Correction to this article has been published in Journal of Hematology & Oncology 2023 16:81

  13. The mRNA-based therapeutics have become the hot spot of biopharmaceutical industries in recent years. The landscape of this area is expanding from infectious disease to cancer, which needs to be summarized to ...

    Authors: Dawei Wu, Lingfeng Hu, Xin Wang, Yue Yu, Shuo-Peng Jia, Hui-Yao Huang, Zi-Wei Li, Jin-Feng Ma, Hai-Bo Zhu, Yu Tang and Ning Li
    Citation: Journal of Hematology & Oncology 2023 16:75
  14. Early detection and diagnosis of many cancers is very challenging. Late stage detection of a cancer always leads to high mortality rates. It is imperative to develop novel and more sensitive and effective diag...

    Authors: Xiangyi Kong, Peng Gao, Jing Wang, Yi Fang and Kuo Chu Hwang
    Citation: Journal of Hematology & Oncology 2023 16:74
  15. Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest s...

    Authors: Nicholas J. Short, Muharrem Muftuoglu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban-Bravo, Yesid Alvarado, Mahesh Basyal, Naval Daver, Courtney D. Dinardo, Gautam Borthakur, Nitin Jain, Maro Ohanian, Elias Jabbour, Ghayas C. Issa, Wei Qiao…
    Citation: Journal of Hematology & Oncology 2023 16:73
  16. Tumor-associated myeloid cells (TAMCs) are among the most important immune cell populations in the tumor microenvironment, and play a significant role on the efficacy of immune checkpoint blockade. Understandi...

    Authors: Xinyu Cheng, Huilan Wang, Zhongyu Wang, Bo Zhu and Haixia Long
    Citation: Journal of Hematology & Oncology 2023 16:71
  17. Multiple myeloma is preceded by monoclonal gammopathy of undetermined significance (MGUS). Serum markers are currently used to stratify MGUS patients into clinical risk groups. A molecular signature predicting...

    Authors: Fumou Sun, Yan Cheng, Jun Ying, David Mery, Samer Al Hadidi, Visanu Wanchai, Eric R. Siegel, Hongwei Xu, Dongzheng Gai, Timothy Cody Ashby, Clyde Bailey, Jin-Ran Chen, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Siegfried Janz…
    Citation: Journal of Hematology & Oncology 2023 16:70
  18. We developed a 13-mer locked nucleic acid (LNA) inhibitor of miR-221 (LNA-i-miR-221) with a full phosphorothioate (PS)-modified backbone. This agent downregulated miR-221, demonstrated anti-tumor activity agai...

    Authors: Pierfrancesco Tassone, Maria Teresa Di Martino, Mariamena Arbitrio, Lucia Fiorillo, Nicoletta Staropoli, Domenico Ciliberto, Alessia Cordua, Francesca Scionti, Bernardo Bertucci, Angela Salvino, Mariangela Lopreiato, Fredrik Thunarf, Onofrio Cuomo, Maria Cristina Zito, Maria Rosanna De Fina, Amelia Brescia…
    Citation: Journal of Hematology & Oncology 2023 16:68
  19. Exosomal circRNA serves a novel genetic information molecule, facilitating communication between tumor cells and microenvironmental cells, such as immune cells, fibroblasts, and other components, thereby regul...

    Authors: Fan Zhang, Jiajia Jiang, Hui Qian, Yongmin Yan and Wenrong Xu
    Citation: Journal of Hematology & Oncology 2023 16:67
  20. Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately, followed by rapid disease recurrence...

    Authors: Charles M. Rudin, Martin Reck, Melissa L. Johnson, Fiona Blackhall, Christine L. Hann, James Chih-Hsin Yang, Julie M. Bailis, Gwyn Bebb, Amanda Goldrick, John Umejiego and Luis Paz-Ares
    Citation: Journal of Hematology & Oncology 2023 16:66
  21. Hematologic malignancies (HMs) pose a serious threat to patients’ health and life, and the five-year overall survival of HMs remains low. The lack of understanding of the pathogenesis and the complex clinical ...

    Authors: Jinxin Li, Qiwei Wang, Yingli Han, Lingli Jiang, Siqi Lu, Beini Wang, Wenchang Qian, Meng Zhu, He Huang and Pengxu Qian
    Citation: Journal of Hematology & Oncology 2023 16:65
  22. Early detection is critical for improving the survival of breast cancer (BC) patients. Exhaled breath testing as a non-invasive technique might help to improve BC detection. However, the breath test accuracy f...

    Authors: Jiaqi Liu, Haibin Chen, Yalun Li, Yanman Fang, Yang Guo, Shuangquan Li, Juan Xu, Ziqi Jia, Jiali Zou, Gang Liu, Hengyi Xu, Tao Wang, Dingyuan Wang, Yiwen Jiang, Yang Wang, Xuejie Tang…
    Citation: Journal of Hematology & Oncology 2023 16:63
  23. The cytotoxicity of NK cells is largely dependent on IgG Fc receptor CD16a, which mediates antibody-dependent cell-mediated cytotoxicity (ADCC). The high-affinity and non-cleavable CD16 (hnCD16) is developed a...

    Authors: Fanyi Meng, Siqi Zhang, Juan Xie, Yuan Zhou, Qingling Wu, Binyan Lu, Shixin Zhou, Xiangyu Zhao and Yang Li
    Citation: Journal of Hematology & Oncology 2023 16:62
  24. B cell maturation antigen (BCMA)-targeted immunotherapy has shown unprecedented results in the treatment of relapsed or refractory (R/R) multiple myeloma (MM). However, disease progression remains an issue att...

    Authors: Jieyun Xia, Zhenyu Li and Kailin Xu
    Citation: Journal of Hematology & Oncology 2023 16:60
  25. Amino acids are basic nutrients for immune cells during organ development, tissue homeostasis, and the immune response. Regarding metabolic reprogramming in the tumor microenvironment, dysregulation of amino a...

    Authors: Luming Yang, Zhaole Chu, Meng Liu, Qiang Zou, Jinyang Li, Qin Liu, Yazhou Wang, Tao Wang, Junyu Xiang and Bin Wang
    Citation: Journal of Hematology & Oncology 2023 16:59
  26. We compared outcomes of adult patients with secondary acute myeloid leukemia (sAML) versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide ...

    Authors: Arnon Nagler, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Lucia Lopez Corral, Stefania Bramanti, Simona Sica, Mi Kwon, Yener Koc, Jiri Pavlu, Alexander Kulagin, Alessandro Busca, Arancha Bermúdez Rodríguez, Péter Reményi, Christoph Schmid, Eolia Brissot…
    Citation: Journal of Hematology & Oncology 2023 16:58

    The Correction to this article has been published in Journal of Hematology & Oncology 2023 16:106

  27. Haemophagocytic lymphohistiocytosis (HLH) is a lethal syndrome of excessive immune activation. We undertook a nationwide study in England of all cases of HLH diagnosed between 2003 and 2018, using linked elect...

    Authors: Joe West, Peter Stilwell, Hanhua Liu, Lu Ban, Mary Bythell, Tim Card, Peter Lanyon, Vasanta Nanduri, Judith Rankin, Mark Bishton and Colin Crooks
    Citation: Journal of Hematology & Oncology 2023 16:56
  28. Muscle wasting is a consequence of physiological changes or a pathology characterized by increased catabolic activity that leads to progressive loss of skeletal muscle mass and strength. Numerous diseases, inc...

    Authors: Tania Setiawan, Ita Novita Sari, Yoseph Toni Wijaya, Nadya Marcelina Julianto, Jabir Aliyu Muhammad, Hyeok Lee, Ji Heon Chae and Hyog Young Kwon
    Citation: Journal of Hematology & Oncology 2023 16:54
  29. Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2V617F mutation and subsequent development of JAK inhib...

    Authors: Andrew Wang, James Liu and Jeffrey J. Pu
    Citation: Journal of Hematology & Oncology 2023 16:53
  30. Authors: Muhammad Elnaggar, Sarita Agte, Paula Restrepo, Meghana Ram, David Melnekoff, Christos Adamopoulos, Mark M. Stevens, Katerina Kappes, Violetta Leshchenko, Daniel Verina, Sundar Jagannath, Poulikos I. Poulikakos, Samir Parekh and Alessandro Laganà
    Citation: Journal of Hematology & Oncology 2023 16:52

    The original article was published in Journal of Hematology & Oncology 2022 15:109

  31. QL1706 (PSB205) is a single bifunctional MabPair (a novel technical platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and anti-CTLA-4 IgG1), with a shorter elimination half-l...

    Authors: Yuanyuan Zhao, Yuxiang Ma, Aimin Zang, Ying Cheng, Yiping Zhang, Xiangcai Wang, Zhendong Chen, Song Qu, Jianbo He, Chuanben Chen, Chuan Jin, Dongyuan Zhu, Qingshan Li, Xianling Liu, Wuyun Su, Yi Ba…
    Citation: Journal of Hematology & Oncology 2023 16:50
  32. Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not require immediate ther...

    Authors: Narendranath Epperla, Rina Li Welkie, Pallawi Torka, Geoffrey Shouse, Reem Karmali, Lauren Shea, Andrea Anampa-Guzmán, Timothy S. Oh, Heather Reaves, Montreh Tavakkoli, Kathryn Lindsey, Irl Brian Greenwell, Emily Hansinger, Colin Thomas, Sayan Mullick Chowdhury, Kaitlin Annunzio…
    Citation: Journal of Hematology & Oncology 2023 16:49
  33. Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiologic agent of several human cancers, including Kaposi’s sarcoma (KS) and primary effusion lymphoma (PEL), which preferentially arise in immunocompromi...

    Authors: Jungang Chen, Zhen Lin, Jiao Song, Karlie Plaisance-Bonstaff, Jennifer James, Shengyu Mu, Steven R. Post, Lu Dai and Zhiqiang Qin
    Citation: Journal of Hematology & Oncology 2023 16:48
  34. COVID-19 inactivated vaccine-induced humoral responses in patients with lung cancer (LCs) to SARS-CoV-2 wild-type (WT) strain and variants BA.4/5 after the primary 2-dose and booster vaccination remained unkno...

    Authors: Chen Chen, Liyuan Dai, Cuiling Zheng, Haolong Li, Xiaomeng Li, Mengwei Yang, Ruyun Gao, Jiarui Yao, Zhishang Zhang, Yuankai Shi and Xiaohong Han
    Citation: Journal of Hematology & Oncology 2023 16:47
  35. Bone metastasis is the leading cause of death in patients with prostate cancer (PCa) and currently has no effective treatment. Disseminated tumor cells in bone marrow often obtain new characteristics to cause ...

    Authors: Xinyu Ye, Xin Huang, Xing Fu, Xiao Zhang, Risheng Lin, Wen Zhang, Jian Zhang and Yi Lu
    Citation: Journal of Hematology & Oncology 2023 16:46
  36. Dysregulation of the Notch signaling pathway, which is highly conserved across species, can drive aberrant epigenetic modification, transcription, and translation. Defective gene regulation caused by dysregula...

    Authors: Xinxin Li, Xianchun Yan, Yufeng Wang, Balveen Kaur, Hua Han and Jianhua Yu
    Citation: Journal of Hematology & Oncology 2023 16:45
  37. Historically, adults with relapsed-refractory acute lymphoblastic leukemia (ALL) experienced poor outcomes with intensive chemotherapy. This mature analysis explores the benefit of the addition of sequential b...

    Authors: Hagop Kantarjian, Fadi G. Haddad, Nitin Jain, Koji Sasaki, Nicholas J. Short, Sanam Loghavi, Rashmi Kanagal-Shamanna, Jeffrey Jorgensen, Issa Khouri, Partow Kebriaei, Yesid Alvarado, Tapan Kadia, Shilpa Paul, Guillermo Garcia-Manero, Bouthaina Dabaja, Musa Yilmaz…
    Citation: Journal of Hematology & Oncology 2023 16:44
  38. Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop T...

    Authors: Carolina Pavlovsky, Bianca Vasconcelos Cordoba, María Belén Sanchez, Beatriz Moiraghi, Ana Varela, Rosario Custidiano, Isolda Fernandez, Maria Josefina Freitas, Maria Verónica Ventriglia, Georgina Bendek, Romina Mariano, María José Mela Osorio, Miguel Angel Pavlovsky, Ana García de Labanca, Cecilia Foncuberta, Isabel Giere…
    Citation: Journal of Hematology & Oncology 2023 16:43
  39. Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax combined with azacitidine plus homoharringto...

    Authors: Hua Jin, Yu Zhang, Sijian Yu, Xin Du, Na Xu, Ruoyang Shao, Dongjun Lin, Yanqiu Chen, Jie Xiao, Zhiqiang Sun, Lan Deng, Xinquan Liang, Hongyu Zhang, Ziwen Guo, Min Dai, Pengcheng Shi…
    Citation: Journal of Hematology & Oncology 2023 16:42
  40. Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unpr...

    Authors: Si-Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, Si-Yang Liu, Yangqiu Li and Yi-Long Wu
    Citation: Journal of Hematology & Oncology 2023 16:40
  41. Cancer patients, due to their immunocompromised status, are at an increased risk for severe SARS-CoV-2 infection. Since severe SARS-CoV-2 infection causes multiple organ damage through IL-6-mediated inflammati...

    Authors: Yan Leyfman, Nancy Emmanuel, Gayathri P. Menon, Muskan Joshi, William B. Wilkerson, Jared Cappelli, Timothy K. Erick, Chandler H. Park and Pushpa Sharma
    Citation: Journal of Hematology & Oncology 2023 16:39

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here